结核病患者非去极化肌松药的药效学特点

doi:10.19871/j.cnki.xfcrbzz.2021.02.019

摘要/Abstract

摘要： 非去极化肌松药（NDMR）是目前临床应用最为广泛的骨骼肌松弛药。NDMR的药效学特征与多种因素有关,结核病患者因其病理生理特点和患者长期服药治疗可引起肝功能及神经-肌肉系统受损,影响该类药物的阻滞时效。了解结核病患者NDMR的药效学特点,对该类患者围术期个体化用药具有重要意义。

关键词: 结核病, 非去极化肌松药, 药效学

Abstract: Non-depolarizing muscle relaxants (NDMR) are the most widely used skeletal muscle relaxants in clinical practice. The pharmacodynamic characteristics of NDMR are related to many factors. Tuberculosis (TB) patients would cause liver dysfunction and neuro-muscular system damage due to their pathophysiological characteristics and long-term medication treatment, which affects the blocking time of NDMR. To understand the characteristics of tuberculosis on the pharmacology of NDMR is of great significance for individualized medication in perioperative period.

Key words: Tuberculosis, Non-depolarizing muscle relaxants, Pharmacodynamics

刘民强, 洪凤珠, 石浩文, 唐怡敏, 李志超, 何仁亮. 结核病患者非去极化肌松药的药效学特点[J]. 新发传染病电子杂志, 2021, 6(2): 160-162.

Liu Minqiang, Hong Fengzhu, Shi Haowen, Tang Yimin, Li Zhichao, He Renliang. Pharmacodynamic characteristics of non-depolarizing muscle relaxants in patients with tuberculosis[J]. Electronic Journal of Emerging Infectious Diseases, 2021, 6(2): 160-162.

参考文献

[1] KIRMEIER E, ERIKSSON LI, LEWALD H, et al.Post-anaesthesia pulmonary complications after use of muscle relaxants (POPULAR): a multicentre, prospective observational study[J]. Lancet Respir Med, 2019, 7(2):129-140.
[2] MORK EL, KRISTENSEN ML, STORKHOLM JB, et al.Resistance towards nondepolarising muscle relaxants: prolonged onset time: A systematic review[J]. Eur J Anaesthesiol, 2019, 36(7):477-485.
[3] 刘民强, 马明飞, 王华, 等. 结核病患者顺式阿曲库铵ED95的测定[J]. 实用医学杂志, 2015, 31(S): 232-233.
[4] 张锦欣, 陈娟娟, 彭劼. 抗结核药物性肝损伤研究进展[J/CD]. 新发传染病电子杂志, 2019, 4(3):173-176.
[5] SONG J, LIU T, ZHAO Z, et al.Genetic polymorphisms of long noncoding RNA RP11-37B2.1 associate with susceptibility of tuberculosis and adverse events of antituberculosis drugs in west China[J]. J Clin Lab Anal, 2019, 33(5):e22880.
[6] ROSEN LE, OLEA-POPELKA F, DEEM SL, et al.Survey of antituberculosis drug administration and adverse inffects in elephants in north America[J]. J Zoo Wildl Med, 2019, 50(1):23-32.
[7] 任坦坦, 陆普选, 邓国防, 等. 2020WHO全球结核报告:全球与中国关键数据分析[J/CD]. 新发传染病电子杂志, 2020, 5(4): 280-284.
[8] SHABBIR M, AFSAR T, RAZAK S, et al.Phytochemical analysis and Evaluation of hepatoprotective effect of Maytenus royleanus leaves extract against anti-tuberculosis drug induced liver injury in mice[J]. Lipids Health Dis, 2020, 19(1):46.
[9] HONG H, DOOLEY KE, STARBIRD LE, et al.Adverse outcome pathway for aminoglycoside ototoxicity in drug-resistant tuberculosis treatment[J]. Arch Toxicol, 2019, 93(5):1385-1399.
[10] PARK S, JO KW, LEE SD, et al.Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis[J]. Respir Med, 2017, 131:43-48.
[11] PEASE C, HUTTON B, YAZDI F, et al.A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection[J]. Pharmacoepidemiol Drug Saf, 2018, 27(6):557-566.
[12] AZNAR ML, RANDO SEGUR A, MORENO MM, et al.Treatment Outcomes and Adverse Events from a Standardized Multidrug-Resistant Tuberculosis Regimen in a Rural Setting in Angola[J]. Am J Trop Med Hyg, 2019, 101(3):502-509.
[13] KWARA A, YANG H, ANTWI S, et al.Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old[J]. Antimicrob Agents Chemother, 2018, 63(1):e01657-18.
[14] PLAUD B, BAILLARD C, BOURGAIN JL, et al.Guidelines on muscle relaxants and reversal in anaesthesia[J]. Anaesth Crit Care Pain Med, 2020, 39(1):125-142.
[15] KITAJIMA O, YAMAMOTO M, TAKAGI S, et al.Potency estimation of sugammadex for the reversal of moderate rocuronium-induced neuromuscular block: a non-randomized dose-response study[J]. J Anesth, 2020, 34(3):348-351.
[16] 石晓伟, 赵崇法, 郭艳辉, 等. 结核性脓胸顺式阿曲库铵剂量反应曲线的测定[J]. 中国中西医结合外科杂志, 2017, 23(1):48-49+105.
[17] 刘民强, 马明飞, 王华, 等. 结核病患者顺式阿曲库铵ED95的测定[J]. 实用医学杂志, 2015, 31(S): 232-233.
[18] 韩亚坤, 刘民强, 何仁亮, 等. 结核病患者罗库溴铵的量效关系[J]. 实用临床医学, 2016, 17(6): 24-26.
[19] 刘民强, 何仁亮, 刘友, 等. 结核病患者维库溴铵ED95的测定[J]. 实用医学杂志, 2014, 30(S): 38-40.
[20] 刘民强, 黄子原, 汪英, 等. 不同性别结核病患者维库溴铵ED95的测定[J]. 广东医学, 2014, 35(8): 1176-1178.
[21] VARGHESE B, AI-HAJOJ S.First Insight Into the Fluoroquinolone and Aminoglycoside Resistance of Multidrug-Resistant Mycobacterium tuberculosis in Saudi Arabia[J]. Am J Trop Med Hyg, 2017, 96(5):1066-1070.
[22] VARRIQUE RM, LQURETTI GR, MATSUMOTO JA, et al.Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery[J]. J Pharm Pharmacol, 2016, 68(11):1351-1358.
[23] 姬雅君, 王恒林, 周文文, 等. 顺苯磺酸阿曲库铵在腰椎结核手术中的肌松作用[J]. 临床麻醉学杂志, 2015, 31(4):409
[24] 周文文, 王恒林, 张凯, 等. 老年腰椎结核合并骨质疏松患者麻醉诱导应用顺式阿曲库铵的药效学研究[J]. 中国骨质疏松杂志, 2015, 21(2):188-191,198.
[25] 刘民强, 陈爱华, 康京华, 等. 结核病患者维库溴铵药效学参数的测定[J]. 南昌大学学报(医学版), 2015, 55(2): 40-43.
[26] 刘民强, 王华, 李仁宰, 等. 不同性别结核病患者维库溴铵药效学参数的测定[J]. 广东医学, 2014, 35(18): 2844-2846.
[27] 洪木周, 黄小兰, 车邦民, 等. 按体表面积给药测定结核病患者罗库溴铵的药效学参数[J]. 广东医学院学报, 2016, 34(6):609-612.
[28] BOON M, MARTINI C, DAHAN A.Recent advances in neuromuscular block during anesthesia[J]. F1000Res, 2018, 7:167.
[29] CAMMU G, DE WITTE J, DE VEYLDER J, et al.Post operative residual paralysis in outpatients versus inpatients[J]. Anesth Analg, 2006, 102(2): 426-429.
[30] UNTERBUCHNER C, BLOBNER M, PUHRINGER F, et al.Development of an algorithm using clinical tests to avoid post-operative residual neuromuscular block[J]. BMC Anesthesiol, 2017, 17(1):101.